Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00937950 · ClinicalTrials.gov registry record · Phase 3
Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,022
- Enrollment target
NCT00937950 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 2,022 participants.
The verdict
NCT00937950, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,022 participants
- Enrollment target
Study Summary
This study is designed to provide up to four years of annual oncogenic HPV DNA testing and cervical cytology examination for NCT00122681 study subjects who displayed normal cervical cytology but tested positive for oncogenic HPV infection at their last NCT00122681 study visit (Visit 10, Month 48). This follow-up study will also be offered to subjects who were pregnant at their last NCT00122681 study visit (Visit 10, Month 48) so that no cervical sample could be collected at that visit. The objectives \& outcome measures of the primary phase (study 008/580299) are presented in a separate protocol posting (NCT00122681).
Interventions
- OTHER Gynaecological follow-up
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,022 participants |
| Start Date | 2009-08-05 |
| Est. Completion | 2014-01-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00937950
The ClinicalTrials.gov registry entry for NCT00937950 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,022 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gynaecological follow-up is the first listed.
NCT00937950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00937950 about?
NCT00937950 is a clinical study titled "Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects". This study is designed to provide up to four years of annual oncogenic HPV DNA testing and cervical cytology examination for NCT00122681 study subjects who displayed normal cervical cytology but tested positive for oncogenic HPV infection at their last NCT00122681 study visit (Visit 10, Month 48). ...
What is the current status of trial NCT00937950?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,022 participants. The study started on 2009-08-05. Estimated completion is 2014-01-20.
What interventions are being tested in trial NCT00937950?
The interventions under investigation include: Gynaecological follow-up (OTHER).
Who is sponsoring clinical trial NCT00937950?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.